Dr Wojciech Jurczak Gives Insight Into the Phase 2 L-MIND Trial in DLBCL


Wojciech Jurczak, MD, PhD, lead researcher on the L-MIND study evaluating a new treatment combination in diffuse large B-cell lymphoma (DLBCL), gave an overview of the trial results that were presented at the European Hematology Association 2023 Congress.

Wojciech Jurczak, MD, PhD, head of the department of oncology at Maria Sklodowska-Curie National Research Institute of Oncology, spoke about some of the results from the phase 2 L-MIND study evaluating the use of tafasitamab-cxix in combination with lenalidomide in diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2023 Congress.

EHA 2023 took place from June 8 to June 15, 2023 in Frankfurt, Germany.


Can you provide an overview of the phase 2 L-MIND study and its findings?

At EHA, we gave the final report of the L-MIND protocol after 5 years of observation time. The L-MIND [trial] was a rather specific protocol in which lenalidomide was used for the first 12 months with tafasitamab-cxix given from the very first cycle until progression or adverse events. In the protocol, we had all relapsing/refractory diffuse large B-cell lymphoma patients, although we excluded the primary refractory patients. 43% of the patients were refractory to the last line of therapy.

We achieved surprisingly good results, resulting in over 60% of response rates. What we presented here at EHA were the effects of the regimen, which was surprisingly good. We achieved nearly 60% of overall response rates and over 40% of complete responses.

It should be of notice that the patients achieving their response had durable response in the analysis. So the duration of response at 60 months, which is 5 years, revealed that over 60% of the patients were still responding. If we analyze the whole group, the median overall survival was reached at 5 years—it's in a range of 40%.

Another interesting thing this toxicity to of the regimen in the first year. The majority of toxicities could have been credited to lenalidomide, so we observed neutropenia, diarrhea, and other effects that are common for lenalidomide. Starting from the second year, where it was just tafasitamab-cxix. It was one of the best tolerated regimen allowing us to [provide] prolonged...exposure even in elderly comorbid patients.

Related Videos
Dr Seun Ross: Achieving Equity is Necessary to Sustain the Health Care System
dr meredith mckean
Jennifer Sturgill, DO, Central Ohio Primary Care
Kristin Oaks, DO, Central Ohio Primary Care
UPMC Health Plan Neighborhood Center
Donna Fitzsimons
dr erin gillaspie
Nick Ferreyros, Community Oncology Alliance
Javed Butler
Michael Petrosky, MD
Related Content
© 2023 MJH Life Sciences
All rights reserved.